Veraxa Biotech, an oncology company spun out of research at the European Molecular Biology Laboratory (EMBL), has completed its merger with SPAC company Voyager Acquisition Corp. and will be trading as of today on the Nasdaq under the ticker symbol VRXA. For the company, which has roots in the Heidelberg region, the move marks its transition from a research-driven company to a publicly listed biotech developer.
Funding: HMNC and the Long Road to Precision Psychiatry
Latest NewsWith a first $50 million tranche of its Series B financing and a commercial partnership with MEDICE, HMNC Brain Health has secured fresh capital for its depression programmes. The deal marks an important milestone for the Munich-based company – nearly a decade after it first set out to transform psychiatry through precision medicine.
Aplagon raises €4.8m to expand antithrombotic into new Phase II trial
Latest NewsFinnish biotech Aplagon has raised €4.8m to broaden Phase II development of its lead candidate APAC, a first-in-class antiplatelet and anticoagulant therapy for thrombo-inflammatory diseases. The financing will support a new Phase II clinical programme in arteriovenous fistula (AVF) maturation failure in patients with end-stage kidney disease.
Kos Biotechnology raises US$123m for Greek life sciences fund
Latest NewsKos Biotechnology Partners has raised US$123m (€106m) for its inaugural global life sciences fund, marking a notable step for Greece’s still young biotechnology financing ecosystem.
Drug delivery nanogel to transform medical devices
Sponsored PublicationsCM4Cure is focused on substantially improving patient outcomes, improving medical device performance by incorporating drug delivery. Our technology redefines medical device coatings – converting passive barriers into active systems via a unique nanogel able to deliver multiple APIs. Initially focused on iv catheters – >2bn are used globally pa – the platform has potential to reduce infection and thrombosis across a swathe of medical devices
Sensorion drops a gene therapy asset because of Regeneron
Latest NewsSensorion has selected SENS-601, its gene therapy candidate for GJB2-related hearing loss, as its lead gene therapy program after filing clinical trial applications in France and Canada. The French biotech is discontinuing development of its OTOF-targeted therapy SENS-501, citing a changed competitive environment following the approval of Regeneron’s rival gene therapy.
Novartis and Orionis get stuck in with new “molecular glue” R&D deal worth up to $1.4bn
Latest NewsOrionis and Novartis have expanded an existing deal to develop “molecular glue”, with a new agreement worth up to $1.4 billion, aiming to stick small molecule drugs onto challenging and elusive drug targets.
Heidelberg-based Veraxa ventures onto Nasdaq in turbulent market environment
Latest NewsVeraxa Biotech, an oncology company spun out of research at the European Molecular Biology Laboratory (EMBL), has completed its merger with SPAC company Voyager Acquisition Corp. and will be trading as of today on the Nasdaq under the ticker symbol VRXA. For the company, which has roots in the Heidelberg region, the move marks its transition from a research-driven company to a publicly listed biotech developer.
Scenic Biotech joins Michael J. Fox LRRK2 consortium with a novel lysosomal bet on Parkinson’s
Latest NewsScenic Biotech has joined the Michael J. Fox Foundation’s LRRK2 consortium to test a Parkinson’s disease approach that targets neither LRRK2 nor GCase directly.
Sanofi’s $11.6bn Bioverativ purchase looks hit-and miss after phase 3 rare diseases drug runs into trouble
Latest NewsSanofi’s $11.6bn Bioverativ acquisition is back under scrutiny after riliprubart, a rare disease drug inherited through the deal, failed a phase 3 CIDP study. While Altuviiio has become a blockbuster, the latest setback raises fresh questions about whether the Bioverativ pipeline can justify its price tag.
Circio completes NOK300m financing to fund circular RNA platform development
Latest NewsOslo-based Circio has completed a NOK300m (€27m) financing round, extending its runway to the end of 2030 and giving the company funds to advance its circVec circular RNA expression platform toward IND-enabling development and clinical proof-of-concept.